Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
IPCA Laboratories Ltd (IPCA) is a manufacturer and supplier of active pharmaceutical ingredients (APIs) and formulations. The company manufactures various formulations and APIs for various therapeutic segments. It offers products for pain, rheumatology, antimalarials and hair care therapy. IPCA markets its products under the brands Azifast, Azibact, Bisotrol, Bronchosolvin, Calchek, Cardoz, Cartiflex, Celedol, Clarbact and others. It serves wholesalers, distributors, pharmacy chains, hospitals, government institutions and other pharmaceutical companies. The company operates formulation facilities in Madhya Pradesh, Maharashtra, and Gujarat among others. It markets its products across the Americas, Africa, Asia, Australia, and Europe. IPCA is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
No. 125, Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067
Website
https://ipca.com/
Telephone
91 22 62105000
No of Employees
18,043
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IPCALAB (NSE)
Revenue (2025)
$1.1B
7.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
54.7%
(2025 vs 2024)
Market Cap*
$4.6B
Net Profit Margin (2025)
XYZ
43.4%
(2025 vs 2024)
* As of and is in US$
IPCA Laboratories Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Formulations | Azifast/Azibact |
| Active Pharmaceutical Ingredients (APIs) | Bisotrol |
| Bronchosolvin | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Corporate Changes/Expansions | In October, the company launched Ipca Pharmaceuticals GmbH, a new subsidiary, in Germany. |
| 2025 | Contracts/Agreements | In September, the company signed a definitive Technology Transfer and Joint Development Agreement with BioSimilar Sciences PR LLC to speed up affordable biologics to treat patients with cancer and autoimmune disease. |
| 2024 | Regulatory Approval | In December, the company received the necessary approval for closure of its subsidiary, Ipca Pharmaceuticals Ltd SA de CV, Mexico. |
Competitor Comparison
| Key Parameters | IPCA Laboratories Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Aurobindo Pharma Ltd | Cipla Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Mumbai | Hyderabad | Hyderabad | Mumbai |
| State/Province | Maharashtra | Maharashtra | Telangana | Telangana | Maharashtra |
| No. of Employees | 18,043 | 43,000 | 27,527 | 9,107 | 31,369 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Premchand Godha | Chairman | Executive Board | 1975 | - |
| Pranay Godha | Director; Chief Executive Officer; Managing Director | Executive Board | 2008 | - |
| Ajit Kumar Jain | Chief Financial Officer; Managing Director; Director | Executive Board | 2010 | - |
| Prashant Godha | Director | Executive Board | 2011 | - |
| Hitesh Maheshwari | President - Research and Development - Formulations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer